# Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction

Study · id `cardio:ct-nct05050500` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05050500](<https://clinicaltrials.gov/study/NCT05050500>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05050500

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.

## Technical summary

Registry record NCT05050500. Randomized; triple masking; primary purpose treatment. Start 2023-05-08 (actual); primary completion 2024-12-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 143 participants (enrolled count; ClinicalTrials.gov record NCT05050500, source copy `cardio:ctgov-nct05050500-2026-01-05`, retrieved 2026-10-26)
- Started: 2023-05-08 (actual) (ClinicalTrials.gov record NCT05050500, source copy `cardio:ctgov-nct05050500-2026-01-05`, retrieved 2026-10-26)
- Primary completion: 2024-12-30 (actual) (ClinicalTrials.gov record NCT05050500, source copy `cardio:ctgov-nct05050500-2026-01-05`, retrieved 2026-10-26)
- Completion: 2024-12-30 (actual) (ClinicalTrials.gov record NCT05050500, source copy `cardio:ctgov-nct05050500-2026-01-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05050500, source copy `cardio:ctgov-nct05050500-2026-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05050500-2026-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction
- Condition: Myocardial Infarction
- Condition: Diabete Type 2
- Condition: Glucose Intolerance
- Intervention (Drug): Dapagliflozin 10mg/Tab
- Intervention (Drug): control group
- Lead sponsor: Qingdao Central Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Qingdao Central Hospital (`cardio:org-qingdao-central-hospital`)

## Provenance

Content hash: 2c25b96d2bba27241c34360c93246761bb14c1bee2abdc62c04351152b6e15fd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
